Burlington, Ontario–(Newsfile Corp. – December 8, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company“) announced today that it has extended the maturity date of its outstanding secured convertible notes (the “Notes“) previously issued on its private placement financing (the “Financing“) which closed in 2023. The Notes had a …
Read More »Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees
Burlington, Ontario–(Newsfile Corp. – July 3, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company“) announces that it has agreed with its non-management directors (the “Directors“) to issue common shares (the “Debt Shares“) to such Directors in exchange for the cancellation of Director fees owing. Each of the …
Read More »Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario–(Newsfile Corp. – July 3, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company“) announced today that as contemplated in the secured convertible notes (the “Notes“) previously issued on its private placement financing (the “Financing“), and consistent with prior quarters, the Company intends to issue common …
Read More »Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery Technology
Burlington, Ontario–(Newsfile Corp. – May 26, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These …
Read More »Rapid Dose Announces Proposed Debt Settlement
Burlington, Ontario–(Newsfile Corp. – May 9, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”) announces that it has agreed with certain of its creditors (the “Creditors”) to issue up to an aggregate of 2,500,000 common shares (the “Settlement Shares”) to such Creditors in exchange for the …
Read More »Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research
Burlington, Ontario–(Newsfile Corp. – April 8, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce an update to the ongoing collaboration project with the Faculty of Kinesiology & Health …
Read More »Rapid Dose Therapeutics to Showcase Xylistrip, a Dental Product, at Key Tradeshows Across Canada
Burlington, Ontario–(Newsfile Corp. – April 3, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”), a Canadian biotech Company providing proprietary oral delivery platform via sublingual thin film strip technology, is proud to announce its participation at major dental tradeshows across Canada to showcase and provide samples …
Read More »Rapid Dose Therapeutics Corp. Announces Payment in Shares for Quarterly Interest on Secured Debt and Update on Shares for Debt Settlement with Creditors
Burlington, Ontario–(Newsfile Corp. – April 1, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), and consistent with prior quarters, the Company intends to issue common …
Read More »Rapid Dose Therapeutics Corp Announces Proposed Equity Private Placement Financing
Burlington, Ontario–(Newsfile Corp. – February 18, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Company”) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $5,000,000 of gross proceeds, consisting of up to 20,833,333 common shares (the “Common Shares”) at …
Read More »Rapid Dose Therapeutics Advances Collaboration with Global Leader for Market-Ready QuickStrip(R) Nicotine in 2025
Burlington, Ontario–(Newsfile Corp. – January 28, 2025) – Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This agreement aims to finalize …
Read More »
Matribhumi Samachar English